KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Common Equity (2018 - 2025)

Vir Biotechnology's Common Equity history spans 8 years, with the latest figure at $765.3 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 33.48% to $765.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $765.3 million, a 33.48% decrease, with the full-year FY2025 number at $765.3 million, down 33.48% from a year prior.
  • Common Equity hit $765.3 million in Q4 2025 for Vir Biotechnology, down from $796.1 million in the prior quarter.
  • Over the last five years, Common Equity for VIR hit a ceiling of $2.1 billion in Q3 2022 and a floor of $651.0 million in Q1 2021.
  • Historically, Common Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 207.4% in 2022 and later crashed 35.84% in 2025.
  • Tracing VIR's Common Equity over 5 years: stood at $1.4 billion in 2021, then soared by 45.12% to $2.1 billion in 2022, then fell by 23.47% to $1.6 billion in 2023, then decreased by 27.66% to $1.2 billion in 2024, then crashed by 33.48% to $765.3 million in 2025.
  • Business Quant data shows Common Equity for VIR at $765.3 million in Q4 2025, $796.1 million in Q3 2025, and $947.5 million in Q2 2025.